CN114377152B - 一种生物标志物响应型荧光示踪剂及其制备方法和应用 - Google Patents
一种生物标志物响应型荧光示踪剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN114377152B CN114377152B CN202111482551.2A CN202111482551A CN114377152B CN 114377152 B CN114377152 B CN 114377152B CN 202111482551 A CN202111482551 A CN 202111482551A CN 114377152 B CN114377152 B CN 114377152B
- Authority
- CN
- China
- Prior art keywords
- compound
- fluorescent tracer
- reaction
- biomarker
- response type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 46
- 239000000700 radioactive tracer Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000004044 response Effects 0.000 title abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000003068 molecular probe Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 32
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- 238000006482 condensation reaction Methods 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 6
- 229940126214 compound 3 Drugs 0.000 claims description 6
- 238000005893 bromination reaction Methods 0.000 claims description 5
- 229940125898 compound 5 Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 229940125773 compound 10 Drugs 0.000 claims description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 18
- 230000008685 targeting Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000003287 optical effect Effects 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 abstract description 5
- 210000001165 lymph node Anatomy 0.000 abstract description 5
- 230000000007 visual effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000004393 prognosis Methods 0.000 abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 108010049990 CD13 Antigens Proteins 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 238000012632 fluorescent imaging Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- -1 oxybenzoate Chemical compound 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 229960004657 indocyanine green Drugs 0.000 description 3
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100024748 E3 ubiquitin-protein ligase UHRF2 Human genes 0.000 description 2
- 101710131422 E3 ubiquitin-protein ligase UHRF2 Proteins 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- QVZUACRCBPIEKQ-UHFFFAOYSA-N 1-azido-4-iodobutane Chemical compound ICCCCN=[N+]=[N-] QVZUACRCBPIEKQ-UHFFFAOYSA-N 0.000 description 1
- FLHJIAFUWHPJRT-UHFFFAOYSA-N 2,3,3-trimethylindole Chemical compound C1=CC=C2C(C)(C)C(C)=NC2=C1 FLHJIAFUWHPJRT-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000012274 Preoperative evaluation Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- UFCZCJYLUGMEJH-UHFFFAOYSA-N dodecanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCCCCCCCCCC(O)=O UFCZCJYLUGMEJH-UHFFFAOYSA-N 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了一种生物标志物响应型荧光示踪剂及其制备方法和应用。该生物标志物响应型荧光示踪剂具有如式(Ⅰ)~式(Ⅳ)所示结构:本发明提供的生物标志物响应型荧光示踪剂以特定的主体结构作为荧光团,然后在两端分别连接生物标志物响应基团和靶向基团,不仅具有高特异性和灵敏度,还具有较好的安全性、生物相容性和光学稳定性,制备成荧光分子探针,可更为精准地指导肿瘤及微小转移灶(如淋巴结)可视化切除,提高手术疗效和患者预后,有望为人类疾病诊断和治疗中提供一种新的辅助方法。
Description
技术领域
本发明涉及医疗领域,特别涉及一种生物标志物响应型荧光示踪剂及其制备方法和应用。
背景技术
在世界范围内肿瘤病人数目不断增加,尽管诊疗水平和治疗手段都有所提高,但是对高发病率和高死亡率的恶性肿瘤的治愈是远远不足的。手术切除实体肿瘤仍是目前癌症治疗的金标准和首选的策略。然而,术中触诊和目视检查难以确切界定恶性肿瘤与正常的组织,给手术切除肿瘤及淋巴结清扫范围的确定带来很大困难。由于传统的术前成像检查(CT/MRI/PET)具有一定局限性,不适用于外科医生在手术中的成像。因此,迫切需要解决如何对肿瘤进行早期诊断、术前评估以及在术中可视化区分肿瘤及正常组织,以及分辨有无淋巴结转移以及转移范围,实现肿瘤精准切除和转移性淋巴结清扫的问题;以达到最小创伤、最大脏器保护的术中效果。
随着精准外科理念的提出和推广以及体内医学成像技术的发展,特别是荧光成像具有即时性、高分辨率、高特异性等优势,通过在术中对肿瘤及微小转移灶进行实时荧光成像,直观引导肿瘤精准切除和转移性淋巴结的清扫,在精准手术导航技术领域有着可观的应用前景。然而荧光成像术中导航技术的发展和普及使用很大程度依赖于荧光示踪剂的开发。
目前,只有极少数荧光示踪剂如吲哚菁绿和亚甲基蓝应用于外科手术(HuangJiaguo,Pu Kanyi,Near-infrared fluorescent molecular probes for imaging anddiagnosis of nephro-urological diseases.Chem.Sci.2021,12,3379-3392.吲哚菁绿近红外光成像在腹腔镜胃癌根治术中应用中国专家共识(2019版),中国实用外科杂志,2020,40(2),139-144),但其在临床使用中存在诸多缺点:(1)信噪比高,灵敏度低;(2)特异性和靶向性差,体内循环时间短,导致吲哚菁绿显影存在假阴性;(3)光稳定性差,容易导致荧光漂白。以上缺陷导致了现有的示踪剂在手术实时导航中的应用受到较大限制,研发新型高靶向性高灵敏度的生物标志物智能响应型荧光示踪剂十分必要。
发明内容
本发明的目的在于克服现有荧光示踪剂存在的缺陷或不足,提供一种生物标志物响应型荧光示踪剂。本发明提供的生物标志物响应型荧光示踪剂以特定的主体结构作为荧光团,然后在两端分别连接生物标志物响应基团和靶向基团,不仅具有高特异性和灵敏度,还具有较好的安全性、生物相容性和光学稳定性,制备成荧光分子探针,可更为精准地指导肿瘤及微小转移灶可视化切除,提高手术疗效和患者预后,有望为人类疾病诊断和治疗中提供一种新的辅助方法。
本发明的另一目的在于提供上述生物标志物响应型荧光示踪剂的制备方法。
本发明的另一目的在于提供上述生物标志物响应型荧光示踪剂或其药学上可以接受的盐或溶剂合物在制备荧光分子探针中的应用。
为了实现本发明的上述目的,本发明提供了如下技术方案:
一种生物标志物响应型荧光示踪剂,具有如式(Ⅰ)~式(Ⅳ)所示结构:
其中,R1为生物标志物响应基团-A或A-B-,B为自消除基团;
R2为靶向基团;
n为0~10的整数。
本发明以特定的主链结构作为发色团/荧光团,然后两端分别连接生物标志物响应基团和靶向基团,来得到生物标志物响应型荧光示踪剂。其中,荧光团具有较好的量子产率,靶向基团可实现生物标志物响应型荧光示踪剂特异性靶向肿瘤细胞,生物标志物响应基团可被生物标志物激活发生分子结构和光学性能的改变,进而发出较强的荧光信号,并利用荧光成像技术实时监测;本发明提供的生物标志物响应型荧光示踪剂不仅具有高特异性和灵敏度,还具有较好的安全性、生物相容性和光学稳定性。另外,该示踪剂可制备成多种给药方式(静脉注射,腹腔注射或者喷晒)的制剂。以静脉注射方式为例,本发明的生物标志物响应型荧光示踪剂经静脉注射入后,在健康组织中由于组织没有发生病变,生物标志物表达含量非常低,生物标志物响应型荧光示踪剂则不会被生物标志物激活发生分子结构和光学性能的改变,因此正常组织种不会检测到明显的荧光信号;当出现癌变部位时,由于示踪剂具有高靶向性,能够高效的靶向至肿瘤组织,生物标志物响应型荧光示踪剂上的响应基团会被癌变部位高表达的肿瘤生物标志物切除并释放荧光信号,通过荧光成像可实时监测荧光信号,实现不同部位肿瘤组织实时检测和肿瘤手术引导以及转移淋巴结可视化识别,可更为精准地指导肿瘤及微小转移灶可视化切除,提高手术疗效和患者预后,有望为人类疾病诊断和治疗中提供一种新的辅助方法。
根据生物标志物的不同,R1基团可进行对应选取。本发明在此也提供一系列生物标志物相应基团。
优选地,所述生物标志物响应基团A为
经研究,上述生物标志物响应基团与生物标志物之间的特异性激发对应关系如下:
优选地,所述自消除基团为
应当理解的是,自消除基团为时,左侧连接位点与A-连接;自消除基团为/>时,左侧连接位点与A-连接;自消除基团为/>时,右侧连接位点与A-连接。
根据靶向部分的不同,R2基团可进行对应选取。本发明在此也提供一系列靶向基团。
优选地,所述靶向基团为
具体地,靶向基团的具体信息如下:
优选地,所述生物标志物响应型荧光示踪剂具有如下所示结构:
上述生物标志物响应型荧光示踪剂的制备方法,包括如下步骤:
S1:式(1)所示结构的化合物1(4-氨基苯基)甲醇)与R1-H发生缩合反应,得式(2)所示的化合物2;化合物2经溴代反应,得式(3)所示的化合物3,备用;
S2:式(4)所示的化合物4和式(5)所示的化合物5发生取代反应得式(6)所示的化合物6;
S3:化合物6、式(7)所示的化合物7和醋酸酐发生缩合反应得式(8)所示的化合物8;
S4:化合物8发生成环反应得式(9)所示的化合物9,备用;
S5:化合物9和化合物3发生取代反应得到式(10)所示的化合物10;
S6:化合物10和R2-H反应,即得所述生物标志物响应型荧光示踪剂;
反应过程为:
优选地,S1中所述缩合反应的温度为10~30℃,时间为3~24h。
优选地,S1中所述化合物1与R1-H的摩尔比为1:1.1。
优选地,S1的缩合反应的缩合剂为N-乙氧羰基-2-乙氧基-1,2-二氢喹啉、EDC/NHS或HOBT/HBTU中的一种或几种;所述溶剂为乙腈、四氢呋喃或二氯甲烷中的一种或几种。
优选地,S1中所述溴代反应的反应温度为-4~10℃、时间为3~15h。
优选地,S1中所述溴代反应的溶剂为四氢呋喃,二氯甲烷或乙腈中的一种或几种。
优选地,S2中所述取代反应的温度为50~100℃,时间为0.5~3h。
优选地,S2中所述取代反应的溶剂为四氢呋喃或乙腈中的一种或两种。
优选地,S3中所述缩合反应的温度为50~100℃,时间为2~8h。
优选地,S3中所述缩合反应的溶剂为无水醋酐或无水乙醇中的一种或两种。
优选地,S4中所述成环反应的温度为40~70℃,时间为2~10h。
优选地,S 4中所述成环反应的活化剂为碳酸钾、碳酸铯、醋酸钠或醋酸钾中的一种或几种;溶剂为乙腈或N,N二甲基甲酰胺中的一种或几种。
优选地,S5中所述取代反应的温度为50~80℃,时间为2~8h。
优选地,S5中所述取代反应的活化剂为DIPEA,三乙胺、碳酸钾或碳酸铯中的一种或几种,溶剂为乙腈或四氢呋喃中的一种或两种。
优选地,S6中所述反应的温度为10~30℃,时间为3~24h。
优选地,S6中所述反应的溶剂为水、DMSO或四氢呋喃中的一种或几种,催化剂为抗坏血酸钠、硫酸铜或溴化亚铜中的一种或几种。
上述生物标志物响应型荧光示踪剂及其药学上可接受的盐或溶剂化物、对映异构体、非对映异构体、互变异构体在制备荧光分子探针中的应用也在本发明的保护范围内。
优选地,所述药学上可接受的盐为盐酸盐、氢溴酸盐、硝酸盐、甲基硝酸盐、硫酸盐、硫酸氢盐、氨基硫酸盐、磷酸盐、乙酸盐、羟基乙酸盐、苯基乙酸盐、丙酸盐、丁酸盐、异丁酸盐、戊酸盐、马来酸盐、羟基马来酸盐、丙烯酸盐、延胡索酸盐、苹果酸盐、酒石酸盐、柠檬酸盐、水杨酸盐、对氨基水杨酸盐、乙醇酸盐、乳酸盐、庚酸盐、邻苯二甲酸盐、草酸盐、琥珀酸盐、苯甲酸盐、邻乙酰氧基苯甲酸盐、氯苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、羟苯酸盐、甲氧基苯甲酸盐、扁桃酸盐、丹宁酸盐、甲酸盐、硬脂酸盐、抗坏血酸盐、棕榈酸盐、油酸盐、丙酮酸盐、双羟奈酸盐、丙二酸盐、月桂酸盐、戊二酸盐、谷氨酸盐、丙酸酯月桂硫酸盐(estolate)、甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、对氨基苯磺酸盐、对甲苯磺酸盐(甲苯磺酸盐)和萘-2-磺酸盐等。
相对于现有技术,本发明具有如下的优点及效果:
本发明提供的生物标志物响应型荧光示踪剂以特定的主体结构作为荧光团,然后在两端分别连接生物标志物响应基团和靶向基团,不仅具有高特异性和灵敏度,还具有较好的安全性、生物相容性和光学稳定性,制备成荧光分子探针,可更为精准地指导肿瘤及微小转移灶可视化切除,提高手术疗效和患者预后,有望为人类疾病诊断和治疗中提供一种新的辅助方法。
附图说明
图1为实施例1~10中各化合物的合成示意图;
图2为荧光示踪剂CyOARGD在有和无丙氨酸氨基肽酶存在的情况下的紫外吸收光谱变化;
图3为荧光示踪剂CyOARGD在有和无丙氨酸氨基肽酶存在的情况下的荧光光谱变化;
图4为荧光示踪剂CyOARGD在有和无丙氨酸氨基肽酶存在的情况下的荧光成像变化;
图5为荧光示踪剂CyOARGD在其他分析物存在情况下的荧光光谱变化,显示其对丙氨酸氨基肽酶的特异性;
图6为荧光示踪剂CyOARGD在HepG2细胞中的荧光成像;
图7为荧光示踪剂CyOARGD在小鼠原位肝癌中的荧光成像;
图8为荧光示踪剂CyOARGD在小鼠原位肝癌中其他器官的荧光成像。
具体实施方式
以下结合实施例和附图进一步解释本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明,本发明所用试剂和材料均为市购。
实施例1化合物2的合成
((9H-芴-9-基)甲氧基)羰基)丙氨酸(0.62g,2.0mmol)溶解在乙腈(20mL)中,然后添加(4-氨基苯基)甲醇(0.98g,8.0mmol,化合物1)和N-乙氧羰基-2-乙氧基-1,2-二氢喹啉(2.0g,8.0mmol)。在25℃下搅拌混合物24小时,然后在真空下进行浓缩。用用二氯甲烷萃取的蒸馏水洗涤残渣,并在真空下浓缩,然后进行HPLC纯化,得到化合物2(0.66g,81%)。1HNMR(300MHz,CDCl3):δ1.47(d,J=9Hz,3H),4.23(t,1H),4.45(d,J=9Hz,2H),4.66(s,2H),7.30(d,J=9Hz,4H),7.32(t,2H),7.49(d,J=9Hz,2H),7.58(d,J=6Hz,2H),7.75(d,J=6Hz,2H)。ESI-MS(m/z):计算值:416.17,谱图显示:416.84。
实施例2化合物3的合成
将化合物2(0.42g,1.0mmol)溶解于四氢呋喃(15mL)中,然后添加三溴化磷(PBr3)(0.54g,2.0mmol)。反应混合物在0℃下搅拌12h,然后用蒸馏水淬灭,然后用二氯甲烷萃取并在真空下浓缩。通过制备性HPLC纯化残留物,得到化合物3(0.38g,80%产率)。1HNMR(300MHz,CDCl3):δ1.46(d,J=6Hz,3H),4.17(t,1H),4.44(m,4H),4.65(s,2H),7.30(t,4H),7.31(t,2H),7.47(d,J=6Hz,2H),7.55(t,2H),7.76(d,J=6Hz,2H)。ESI-MS(m/z):计算值:478.09,谱图显示[m-溴]:399.50。
实施例3化合物5的合成
将2,3,3-三甲基-3H-吲哚(化合物4,640mg,4mmol)和1-叠氮-4-碘代丁烷(900mg,4mmol)的混合物在25mL圆底烧瓶中,90℃无溶剂条件下加热1小时。将混合物冷却至室温并在乙醚中沉淀。粗产物用乙醚洗涤以获得化合物5(化合物5,1220mg),在下一步中使用,无需进一步纯化。薄层色谱(硅胶、乙酸乙酯/石油醚;1/5)Rf=0.52。1HNMR(300MHz,CDCl3):δ1.67(s,6H),1.83(m,2H),2.14(m,2H),3.20(s,3H),3.50(t,2H),4.80(t,2H),7.62(m,3H),7.81(dd,1H)。LRMS(m/z):计算值:257.1,谱图显示:257.2。
实施例4化合物7的合成
将溴盐(化合物5,780mg,2.0mmol)、化合物6(270mg,1.0mmol)和无水乙酸钠(250mg,3.0mmol)在10mL醋酸酐中的混合物回流(80℃)6小时。反应混合物冷却至室温,然后减压浓缩,得到棕绿色残渣。用二氯甲烷/甲醇(20/1)通过硅胶柱层析纯化残余物。获得绿色固体(化合物7,1300mg,产率85%)。薄层色谱(硅胶、二氯甲烷/甲醇;20/1)Rf=0.43。1HNMR(300MHz,CDCl3):δ1.70(s,12H),1.85(m,4H),2.00(m,6H),2.80(t,4H),3.48(t,4H),4.31(t,4H),6.32(d,2H),7.20(m,2H),7.25(d,1H),7.30(d,1H),7.40(m,4H),8.30(d,2H)。LRMS(m/z):计算值:649.3,谱图显示:649.3。
实施例5化合物8的合成
将间苯二酚(220mg,2.0mmol)和碳酸钾(276mg,2.0mmol)在乙腈(10mL)中的混合物在50℃下搅拌20min。然后,通过注射器将化合物7(776mg,1.0mmol)在乙腈(10mL)中的溶液加入到上述混合物中,并在55℃下加热反应混合物3h。在减压下蒸发溶剂,并使用二氯甲烷/甲醇(10/1,v/v)作为洗脱剂通过硅胶柱层析纯化粗产物,以得到绿色固体的所需化合物8。薄层色谱(硅胶、二氯甲烷/甲醇;20/1)Rf=0.51。1HNMR(300MHz,CDCl3):δ1.75(s,6H),1.98(m,8H),2.70(m,2H),3.45(t,2H),4.20(t,2H),5.30(s,1H),6.10(d,1H),7.15(m,3H),7.42(m,4H),7.73(d,1H),8.50(d,1H)。LRMS(m/z):计算值:467.2,谱图显示:467.2。
实施例6化合物9的合成
向化合物8(46.80mg,0.1mmol)在乙腈(8mL)中的溶液中添加化合物3(1.44g,0.3mmol)和N,N-二异丙基乙胺(80μl,0.62mmol)。在70℃下搅拌反应混合物6h后,将其倒入蒸馏水中,用二氯甲烷萃取并在真空下浓缩以得到产物。向残渣中添加哌啶(0.8mL)和二甲基甲酰胺(2mL),并在25℃下搅拌15分钟,然后在真空下进行浓缩。通过制备性HPLC进一步纯化,得到蓝色固体的化合物9(48mg,76%)。1HNMR(300MHz,CD3OD):δ1.56(s,3H),1.85(m,8H),1.94(m,4H),2.80(t,4H),3.30(t,2H),4.06(m,1H),4.40(m,2H),5.26(s,2H),6.50(d,J=15Hz,1H),7.15(m,1H),7.45(m,1H),7.55(m,7H),7.70(m,3H),8.75(d,J=15Hz,1H)。
实施例7化合物10(CyOARGD)的合成
将化合物9(24mg,0.038mmol)和丙炔基RGD(64mg,0.04mmol)溶解于二甲基亚砜/水(4ml/4ml)中。加入抗坏血酸钠(8.20mg,0.04mmol)和五水硫酸铜(16.60mg,0.066mmol)在水中的溶液。在25℃下,在氮气气氛下和黑暗中搅拌混合物16h后,在丙酮中进行沉淀。通过制备性HPLC进一步纯化,得到蓝色固体示踪剂CyOARGD(化合物10,89mg,90%产率)。(300MHz,CD3OD):δ0.90(m,4H),0.92(m,4H),0.92(m,4H),0.92(m,2H),0.92(m,2H),1.32(m,6H),1.32(m,6H),1.32(m,6H),1.32(m,6H),1.32(m,6H),1.32(m,6H),1.32(m,6H,6H),1.32(m,6H),1.32(m,6H),1.32(m,6H),1.6,(m,6H),1.32(m,6H),1.32(m,6,(m,6H),1.6,(m,6,(m,6),1.6),1.6,(1.6,(1.6,(1.6),1.32(m,6H),1.6),1.32(m,6),1.6,(m,6,(1.51(d,J=15,1H),7.14-7.44(m,2H),7.56(m,7H),7.67(m,3H),8.78(d,J=15Hz,1H)。ESI-MS(m/z):计算值:1326.68,谱图显示:1326.96。
CyOARGD的结构式如下:
实施例1~10中各化合物的反应过程如图1。
性能测试:
光谱测试:
将10μM的CyOARGD溶液与丙氨酸氨基肽酶溶液在37℃的缓冲溶液中孵育。孵育后测定溶液的紫外可见光谱和荧光光谱。采用IVIS系统采集荧光图像,激发波长为675±10nm,发射波长为720±10nm,采集时间为0.1s。
测试结果如图2,从图2可知,CyOARGD的最大吸收波长在600nm,CyOARGD溶液与丙氨酸氨基肽酶溶液孵育后的最大吸收波长在690nm。
测试结果如图3,从图3可知,CyOARGD的最大发射波长在720nm,CyOARGD溶液与丙氨酸氨基肽酶溶液孵育后的最大吸收波长720nm有明显增长,增长倍数达到12倍。
测试结果如图4,从图4可知,CyOARGD基本无荧光成像信号,CyOARGD溶液与丙氨酸氨基肽酶溶液孵育后有很强的荧光成像信号。
测试结果如图5,从图5可知,CyOARGD与其他分析物存在情况下的荧光光谱基本无变化,仅与丙氨酸氨基肽酶溶液孵育后有明显荧光变化,显示其对丙氨酸氨基肽酶的特异性。
细胞成像:
HepG-2细胞培养于10%胎牛血清(FBS)、100U/ml青霉素和100μg/ml链霉素的DMEM培养基中,孵箱条件37℃,5%空气湿度。对于细胞荧光成像实验,将HepG-2细胞(每孔1×105个细胞于1ml DMEM细胞培养基中)接种到共聚焦细胞培养皿(直径35mm)中并培养过夜,细胞与CyOARGD(10μM)共孵育60分钟,然后弃培养基,用PBS缓冲液冲洗细胞三次;细胞用4%多聚甲醛溶液固定,并用4,6-二脒基-2-苯基吲哚(DAPI)染色。使用激光扫描显微镜LSM800(蔡司)拍摄细胞荧光图像。CyOARGD的激发波长和发射波长为640/655-710nm,Hoechst的激发波长和发射波长为405/410-470nm。
原位肝肿瘤小鼠模型的建立:
随机选取Balb/c裸鼠,将含HepG-2细胞和PBS基质凝胶的混悬液注射至小鼠肝左外侧叶。肿瘤植入后14天后进行影像学检查。
活体小鼠肿瘤的实时体内NIRF成像:
对于原位肝肿瘤模型,在肿瘤植入14天后,再静脉注射CyOARGD(10μmol/kg)后6小时进行实时NIRF成像。使用IVIS spectrumCT系统采集荧光图像,激发波长为675±10nm,发射波长为720±10nm,采集时间为1s。小鼠在注射CyOARGD 6小时后被安乐死,处死后对小鼠切除的器官进行成像。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,对于本领域的普通技术人员来说,在上述说明及思路的基础上还可以做出其它不同形式的变化或变动,这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明权利要求的保护范围之内。
Claims (5)
1.一种生物标志物响应型荧光示踪剂,其特征在于,所述荧光示踪剂具有如下所示结构:
。
2.权利要求1所述生物标志物响应型荧光示踪剂的制备方法,其特征在于,包括如下步骤:
S1:式(1)所示结构的化合物1与R1-H发生缩合反应,得式(2)所示的化合物2;化合物2经溴代反应,得式(3)所示的化合物3,备用;
S2:式(4)所示的化合物4和式(5)所示的化合物5发生取代反应得式(6)所示的化合物6;
S3:化合物6、式(7)所示的化合物7和醋酸酐发生缩合反应得式(8)所示的化合物8;
S4:化合物8发生成环反应得式(9)所示的化合物9,备用;
S5:化合物9和化合物3发生取代反应得到式(10)所示的化合物10;
S6:化合物10和R2-H反应,即得所述生物标志物响应型荧光示踪剂;
其中,R1为,n=0。
3. 根据权利要求2所述制备方法,其特征在于,S1中所述缩合反应的温度为10~30℃,时间为3~24 h;S1中所述溴代反应的反应温度为-4~10℃,时间为3~15 h。
4. 根据权利要求2所述制备方法,其特征在于,S2中所述取代反应的温度为50~100℃,时间为0.5~3 h;
S3中所述缩合反应的温度为50~100℃,时间为2~8 h;
S4中所述成环反应的温度为40~70℃,时间为2~10 h;
S5中所述取代反应的温度为50~80℃,时间为2~8 h;
S6中所述反应的温度为10~30℃,时间为3~24 h。
5.权利要求1所述生物标志物响应型荧光示踪剂及其药学上可接受的盐在制备荧光分子探针中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111482551.2A CN114377152B (zh) | 2021-12-06 | 2021-12-06 | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111482551.2A CN114377152B (zh) | 2021-12-06 | 2021-12-06 | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114377152A CN114377152A (zh) | 2022-04-22 |
CN114377152B true CN114377152B (zh) | 2024-04-02 |
Family
ID=81196157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111482551.2A Active CN114377152B (zh) | 2021-12-06 | 2021-12-06 | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114377152B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111185228B (zh) * | 2020-02-23 | 2022-11-04 | 吉林大学 | 一种碳化聚合物点/钙钛矿复合光催化剂、制备方法及其在光催化裂解hi产氢方面的应用 |
CN115947946B (zh) * | 2022-12-13 | 2023-11-07 | 中山大学 | 一种肾清除型双通道光学纳米探针及其制备方法和应用 |
CN116621820A (zh) * | 2023-05-23 | 2023-08-22 | 中山大学 | 一种两性离子荧光化合物及其制备方法和应用 |
CN117186151B (zh) * | 2023-08-23 | 2024-05-17 | 中山大学 | 一种近红外两性离子花菁染料及其制备方法和应用 |
-
2021
- 2021-12-06 CN CN202111482551.2A patent/CN114377152B/zh active Active
Non-Patent Citations (3)
Title |
---|
Shasha He.Near-Infrared Fluorescent Macromolecular Reporters for Real-Time Imaging and Urinalysis of Cancer Immunotherapy.《Journal of the American Chemical Society》.2020,全文. * |
Xiao Zhou.An APN-activated NIR photosensitizer for cancer photodynamic therapy and fluorescence imaging.《Biomaterials》.2020,全文. * |
Zhiliang Luo.Targeted Delivery of a γ-lutamyl Transpeptidase Activatable NearInfrared-Fluorescent Probe for Selective Cancer Imaging.《Analytical Chemistry》.2018,第2875-2883页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114377152A (zh) | 2022-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114377152B (zh) | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 | |
US10898591B2 (en) | Compositions and methods for assessing eye vasculature | |
CN109370247A (zh) | 共轭链功能化苯并吲哚七甲川花菁染料及应用 | |
AU2022338581B2 (en) | N,N-DIPHENYLAMINO-MODIFIED β-CARBOLINE INDOLIUM SALT, PREPARATION METHOD AND USE | |
Zhou et al. | Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield | |
EP3323431A1 (en) | Diagnostic for cancer | |
CN113979912B (zh) | 两种前列腺特异性膜抗原靶向荧光探针及其制备方法与应用 | |
US20240083880A1 (en) | Near-infrared cyanine dyes and conjugates thereof | |
CN115947777A (zh) | 一种近红外二区荧光化合物及其制备方法与应用 | |
JP2010203966A (ja) | 低酸素領域イメージング用近赤外蛍光プローブ | |
Lu et al. | Log P analyzation-based discovery of GSH activated biotin-tagged fluorescence probe for selective colorectal cancer imaging | |
CN114315791B (zh) | 用于实现手术导航和微小转移瘤成像的小分子化学发光探针及其制备方法和用途 | |
CN115605459A (zh) | 用于标记肿瘤组织的新型荧光化合物 | |
CN116621820A (zh) | 一种两性离子荧光化合物及其制备方法和应用 | |
CN114835629B (zh) | 一类咔唑苯并[cd]吲哚鎓盐及其制备方法与应用 | |
CN117186151B (zh) | 一种近红外两性离子花菁染料及其制备方法和应用 | |
CN116144192A (zh) | 一类半花菁近红外二区染料及其制备方法与用途 | |
TW202330498A (zh) | 用於腫瘤偵測及手術指引之化合物及組合物 | |
CN105802273A (zh) | 基于尼罗蓝母体的荧光识别染料、其制备方法及应用 | |
CN114478480A (zh) | 一种用于癌细胞中环氧合酶-2鉴别的荧光探针 | |
WO2022036331A1 (en) | Compounds and compositions for tumor detection and surgical guidance | |
CN117624177A (zh) | 一种响应过氧化亚硝酸根的荧光探针及其制备方法与应用 | |
WO2023133961A1 (zh) | 一种高灵敏度硫化氢响应型纳米探针及其制备方法和应用 | |
CN116554274A (zh) | 一种用于肿瘤靶向成像的近红外荧光探针的制备法与应用 | |
CN113754642A (zh) | pH响应的半花菁吲哚类化合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |